Article Text

Download PDFPDF
EP1298 Robotic assisted ingunofemoral lymphadenectomy for vulval carcinoma
  1. Y Kulkarni
  1. Gynecologic Oncology, Centre for Cancer, Kokilaben Dhirubhai Ambani Hospital and Research Centre, Mumbai, India


Introduction/Background Vulval carcinoma accounts for 3–5% of all gynaecological cancers. The primary treatment of vulval carcinoma is Local excision ±inguinal lymphadenectomy. Inguinal node status is an important prognostic indicator in predicting outcomes. It makes lymph node assessment Mandatory for all case of vulval carcinoma except the superficially invasive cancers. Sentinel node mapping is a useful technique, still around 50% of women require inguinal lymphadenectomy. Here we demonstrate our technique of Robotic Assisted Inguinal Lymphadenectomy.

Methodology Various techniques have been tried to reduce the morbidity associated with inguinal lymphadenectomy both short term and long term. It includes separate incisions, sentinel node mapping, saphenous sparing and video endoscopic approach. From June 2014 to December 2018, 15 patients of carcinoma vulva underwent 21 (9 unilateral, 6 bilateral) Robotic assisted inguinal lymphadenectomy at our institute. This video demonstrates the port placement and technique of the procedure.

Results 15 patients of vulval carcinoma underwent 21 robotic assisted inguinal lymphadenectomy (9 unilateral/6 bilateral) underwent the procedure. Mean age of patients was 59yrs (32–73). Mean operative time was 69 min and mean blood loss was 40 ml. The mean number of nodes harvested were 13 (8–23). There were no conversions. No intraoperative complications were observed. Postoperative superficial wound infection was seen in two of the twelve cases and prolonged serum aspiration was required in four cases. Final histopathology showed metastasis in 4 of 21 inguinal node dissection procedures.

Conclusion Robotic assisted inguinal lymphadenectomy is safe and feasible with less wound related morbidity that conventional procedure. Need multi-institutional studios to evaluate long term complications, safety and survival data.

Disclosure Nothing to disclose

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.